Status:
ACTIVE_NOT_RECRUITING
eHealth in Treatment of Gestational Diabetes (eMOMGDM)
Lead Sponsor:
Helsinki University Central Hospital
Collaborating Sponsors:
University of Helsinki
Aalto University
Conditions:
Gestational Diabetes
Mobile Application
Eligibility:
FEMALE
18-45 years
Phase:
NA
Brief Summary
The overall aim of the eMOM GDM-project is to develop and evaluate a novel system to clinical decision making and patient behavior change in treatment of GDM, combining diet, physical activity, sleep,...
Detailed Description
200 women with gestational diabetes will be randomized into the intervention and the control group at gestational week (GW) 24-28. Participants in the intervention group will use the eMOM GDM -applic...
Eligibility Criteria
Inclusion
- GDM diagnoses at 24-28 gestational weeks
Exclusion
- type 1 or type 2 diabetes
- use of medication that influences glucose metabolism (such as continuous therapy with oral corticosteroids or metformin)
- multiple pregnancy
- physical disability
- current substance abuse
- severe psychiatric disorder (that complicates participation to the study)
- significant difficulty in cooperating (e.g. inadequate Finnish language skills)
Key Trial Info
Start Date :
March 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04714762
Start Date
March 10 2021
End Date
December 31 2026
Last Update
December 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helsinki University Hospital
Helsinki, Finland, 00029